Tab Linagliptin

# Tab linagliptin ## Overview - **Classification**: Dipeptidyl peptidase-4 (DPP-4) inhibitor - **Mechanism**: Blocks the DPP-4 enzyme, increasing active incretin hormones (GLP-1, GIP). This enhances glucose-dependent insulin secretion and reduces glucagon release. ## Primary Indications 1. **Type 2 Diabetes Mellitus** - As an adjunct to diet and exercise to improve glycemic control. ## Adult Dosing ### Standard Dosing **Type 2 Diabetes Mellitus** - **Dose**: **5 mg** - **Frequency**: Once daily - **Route**: Oral - **Special considerations**: Can be taken with or without food. ### Dose Adjustments - **Renal Impairment**: No dose adjustment required for any degree of renal impairment. - **Hepatic Impairment**: No dose adjustment required. - **Elderly Patients**: No specific dose adjustment needed based on age alone. ## Pediatric Dosing *Linagliptin is **not approved** for use in pediatric patients.* ### Neonates (0-28 days) - **Dose**: Not recommended. - **Frequency**: Not recommended. - **Maximum**: Not applicable. - **Special Notes**: Safety and efficacy have not been established. ### Infants (1-12 months) - **Dose**: Not recommended. - **Frequency**: Not recommended. - **Maximum**: Not applicable. ### Children (1-12 years) - **Dose**: Not recommended. - **Frequency**: Not recommended. - **Maximum**: Not applicable. ### Adolescents (13-18 years) - **Dose**: Not recommended. - **Maximum**: Not applicable. ## Safety Information ### Contraindications - **Absolute**: History of serious hypersensitivity reaction (e.g., anaphylaxis, angioedema, exfoliative skin conditions) to linagliptin. ### Common Adverse Effects - **Common (1-10%)**: Nasopharyngitis, cough, diarrhea, back pain, headache. - **Serious but Rare**: Pancreatitis, bullous pemphigoid, severe arthralgia, hypersensitivity reactions. ### Key Drug Interactions - **P-glycoprotein/CYP3A4 inducers (e.g., rifampin)**: May decrease linagliptin exposure; consider alternative agent. - **Sulfonylureas/Insulin**: Increased risk of hypoglycemia; dose reduction of sulfonylurea/insulin may be required. ## Monitoring & Follow-up - **Before Treatment**: Baseline A1C, and renal function (if not recently assessed). - **During Treatment**: A1C every 3-6 months to assess glycemic control. Monitor for symptoms of pancreatitis. - **Clinical Signs**: Watch for signs of hypoglycemia (especially with concomitant SU/insulin), severe abdominal pain (pancreatitis), unexplained severe joint pain, or skin blistering/erosions (bullous pemphigoid). ## Clinical Pearls - 💡 **Tip 1**: Linagliptin is unique among DPP-4 inhibitors as it requires no dose adjustment for renal or hepatic impairment. - 💡 **Tip 2**: Can be taken once daily with or without food. - 💡 **Tip 3**: Low risk of hypoglycemia when used as monotherapy. - 💡 **Tip 4**: Counsel patients on the symptoms of pancreatitis and bullous pemphigoid. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.